Cybrexa Therapeutics Announces Multiple Oral Presentations Highlighting the Advances in the Application of DNA Repair Pathways in Cancer Drug Development at the DNA Damage Response Therapeutics Summit 2019
22 janv. 2019 07h00 HE
|
Cybrexa Therapeutics
NEW HAVEN, Conn., Jan. 22, 2019 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a biotechnology company developing a new class of cancer therapeutics through its alphalex™ tumor-targeting platform, today...
Cybrexa Therapeutics Selects Lead Clinical Candidate CBX-11, Combining its alphalex™ Technology with an Approved PARP Inhibitor to Treat Various Solid Tumors in Combination with Chemotherapy
02 janv. 2019 07h00 HE
|
Cybrexa Therapeutics
CBX-11 selected based on robust efficacy and safety in combination with chemotherapy demonstrated in preclinical models Positive pre-IND Meeting with FDA supports on track plan to file IND in Q4 2019...
Cybrexa Therapeutics Presents Preclinical Data Demonstrating its alphalex™ Tumor Targeting Platform Delivers a High Dose of PARP Inhibitor in Combination with Chemotherapy
13 nov. 2018 07h00 HE
|
Cybrexa Therapeutics
Synergistic combination selectively kills tumors and prevents bone marrow toxicities Poster presentation today during 30th EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium Marks...
Cybrexa Therapeutics to Present Preclinical Data for its Tumor-Selective Technology Platform at the 30th EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium
05 nov. 2018 08h00 HE
|
Cybrexa Therapeutics
NEW HAVEN, Conn., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a biotechnology company developing a new class of cancer therapeutics through its tumor-selective technology platform, today...
Cybrexa Therapeutics Expands Scientific Advisory Board Ahead of IND Filing
22 oct. 2018 08h38 HE
|
Cybrexa Therapeutics
Dr. Geoffrey Shapiro and Dr. Timothy Yap bring extensive expertise in targeting cell-cycle and DNA repair mechanisms in oncology drug development NEW HAVEN, Conn., Oct. 22, 2018 (GLOBE NEWSWIRE) --...
Cybrexa Therapeutics Appoints Keely Zipp as Vice President of Marketing
08 oct. 2018 08h00 HE
|
Cybrexa Therapeutics
NEW HAVEN, Conn., Oct. 08, 2018 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, an early-stage biotechnology company developing a new class of cancer therapeutics through its tumor-selective technology...